Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system

Journal of Clinical Oncology

Volumn 19, Issue 16, 2001, Pages 3622-3634

  Balch, C M ^a   Soong, S J ^a   Gershenwald, J E ^a   Thompson, J F ^a   Reintgen, D S ^a   Cascinelli, N ^a   Urist, M ^a   McMasters, K M ^a   Ross, M I ^a   Kirkwood, J M ^a   Atkins, M B ^a   Thompson, J A ^a   Coit, D G ^a   Byrd, D ^a   Desmond, R ^a   Zhang, Y ^a   Liu, P Y ^a   Lyman, G H ^a   Morabito, A ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; SCHOOL CHILD; SKIN ULCER; TUMOR VOLUME;

EID: 0035880957     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.16.3622     Document Type: Article

References (81)

1. A multifactorial analysis of melanoma: Prognostic histopathologic features comparing Clark's and Breslow's staging methods
2. Prognostic factors in cutaneous malignant melanoma in stage I: A clinical, morhological and multivariate analysis
3. Stage I melanoma of the skin: Evaluation of prognosis according to histologic characteristics
4. Primary cutaneous melanoma: Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification
5. A long-term analysis of 620 patients with malignant melanoma at a major referral center
6. Critical analysis of the current AJCC staging system for cutaneous melanoma and proposal of a new staging system
7. Classification and staging of melanoma
8. Modifying the criteria of the American Joint Commission on Cancer staging system in melanoma
9. A new AJCC staging system for cutaneous melanoma
10. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
11. Prognostic factors in thin cutaneous malignant melanoma
12. Breslow thickness and Clark level in melanoma: Support for including level in pathology reports and in AJCC staging
13. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness
14. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: Correlation with newly proposed staging system
15. Prognostic factors in thin cutaneous malignant melanoma
16. Predicting ten-year survival of patients with primary cutaneous melanoma: Corroboration of a prognostic model
17. Prognostic histopathologic factors in malignant melanoma
18. Factors affecting survival following local, regional, or distant recurrence from localized melanoma
19. Head and neck melanoma in 534 clinical stage I patients: A prognostic factors analysis and results of surgical treatment
20. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
21. The prognosis of primary and metastasising melanoma: An evaluation of the TNM classification in 2,495 patients
22. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion
23. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51-3.39mm): A conceptual model for tumor growth and metastasis
24. Prognostic groups of patients with stage I melanoma
25. Prognostic factors for stage I melanoma of the skin: A review
26. Cutaneous malignant melanoma (Arizona Cancer Center experience): I. Natural history and prognostic factors influencing survival in patients with stage I disease
27. Prognostic significance of the histological features of malignant melanoma
28. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma
29. Independent prognostic importance of vascular invasion in nodular melanomas
30. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm)
31. Problems in the measurement of tumor thickness and level of invasion in cutaneous melanoma
32. Tumor thickness in evaluating prognosis of cutaneous melanoma
33. Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma
34. Observer variation in histological classification of cutaneous malignant melanoma
35. Thin malignant melanomas and recurrence potential
36. A multifactorial analysis of melanoma: II. Prognostic factors in patients with stage I (localized) melanoma
37. The prognostic significance of ulceration of cutaneous melanoma
38. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama and New South Wales, Australia
39. Efficacy of an elective regional lymph node dissection of 1- to 4-mm thick melanomas for patients 60 years of age and younger
40. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): Results of a multi-institutional randomized surgical trial
41. Ulceration and prognosis in cutaneous malignant melanoma
42. Surgical margins and prognostic factors in patients with thick (> 4 mm) primary melanoma
43. Prognosis of thick cutaneous melanoma
44. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma
45. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985: Prognostic factors and histologic correlations
46. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86 and their subsequent validation
47. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions
48. International pathologists congruence survey on quantitation of malignant melanoma
49. Interobserver variation between pathologists in the classification of cutaneous malignant melanoma in western Australia
50. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?
51. Age as a prognostic factor in the malignant melanoma population
52. Malignant melanoma in the elderly
53. Age as a prognostic factor in the malignant melanoma population
54. Invasive cutaneous melanoma in elderly patients
55. The female superiority in survival in clinical stage II cutaneous malignant melanoma
56. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
57. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The ECOG trial EST 1684
58. Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials
59. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II)
60. Cutaneous melanoma: Prognosis and treatment results worldwide
61. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma
62. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases
63. The prognostic significance of microscopic tumor burden in 925 melanoma patients undergoing sentinel lymph node biopsy
64. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic
65. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes: A multivariate analysis
66. Axillary dissection in melanoma: Prognostic variables in node-positive patients
67. The prognosis of patients with stage III melanoma
68. Prognosis of skin melanoma with regional node metastases (stage II)
69. Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients
70. Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma
71. Prognosis of clinical stage I melanoma patients with positive elective regional node dissection
72. Prognostic factors in 1,521 melanoma patients with distant metastases
73. Prolonged survival of 2 years or longer for patients with disseminated melanoma
74. Prognostic factors for survival of patients treated systemically for disseminated melanoma
75. Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis
76. A multifactorial analysis of melanoma: IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)
77. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive AJCC stage IV melanoma
78. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma
79. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients